<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133637</url>
  </required_header>
  <id_info>
    <org_study_id>29287</org_study_id>
    <nct_id>NCT03133637</nct_id>
  </id_info>
  <brief_title>Ceftriaxone and Jaundice in Neonates</brief_title>
  <acronym>CEFT</acronym>
  <official_title>Effect of Ceftriaxone on Neonatal Jaundice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjiv Amin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftriaxone is an antibiotic often used for the management of sepsis. Neonates commonly have
      jaundice during the first postnatal week. The effect of ceftriaxone on jaundice has not been
      investigated in well designed studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ceftriaxone may affect jaundice concentration specifically binding of bilirubin to
      albumin. The study will evaluate the effect of ceftriaxone on bilirubin binding in neonates
      with a diagnosis of sepsis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in bilirubin binding assays</measure>
    <time_frame>baseline and through study completion, an average of 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Automated brain stem evoke response test</measure>
    <time_frame>through study completion, an average of 1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Jaundice and Sepsis in Neonates</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>Eligible infants will receive ceftriaxone</description>
    <arm_group_label>Ceftriaxone Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants with sepsis requiring IV antibiotics for more than 3 days and who has total
             serum bilirubin &lt; 12 mg/dL but otherwise stable and healthy to be discharged home

        Exclusion Criteria:

          -  Infants with asphyxia, chromosomal disorder, hearing loss, moderate to severe
             jaundice, unstable clinical conditions, respiratory distress, cardiac disorders, and
             any clinical conditions which will preclude discharge to home.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Sanjiv Amin</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaundice</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

